Podimetrics, an organization that helps sufferers with diabetes forestall critical problems, is teaming up with HealthMed, an worker well being and wellness platform.
HealthMed goals to combine Podimetrics’ SmartMat expertise into its portfolio of advantages supposed for big employers, hospitals and municipalities. The corporate additionally supplies worker wellness and psychological well being applications.
Podimetrics’ SmartMat measures the foot temperature of high-risk sufferers and scans for early indicators of irritation that might result in wounds, amputations and diabetic foot ulcers.
“Our partnership with HealthMed is a robust collaboration, and we’re excited to work collectively to help people with complicated diabetes who’re on the biggest threat for critical problems,” Dr. Jon Bloom, CEO of Podimetrics, mentioned in a press release.
“We share a typical mission to concentrate on prevention and enhance well being outcomes. This collaboration is aimed toward reaching that objective collectively.”
Tracy Webster, founding father of HealthMed, mentioned the partnership with Podimetrics and its modern answer for managing difficult diabetes will profit self-insured employers and enhance the continuum of care.
“We look ahead to the optimistic influence we are able to make on well being outcomes and the general value of care,” Webster mentioned in a press release.
THE LARGER TREND
In March, Podimetrics partnered with profit administration group Alivi Well being, which integrated SmartMat expertise into its portfolio of specialty advantages to bolster its podiatry advantages for well being plans and payers.
In 2024, Podimetrics sued Eire-based Bluedrop Medical for patent infringement. Bluedrop has a tool that enables an individual with diabetes to scan their ft for potential cases of foot ulcers.
In response to the compliant, Bluedrop allegedly “immediately and/or by means of subsidiaries, staff, intermediaries or commerce names” dedicated acts of infringement by “importing, providing to promote and promoting an instrumentality that infringes [Podimetrics’] Patents-in-Swimsuit.” The case was dismissed after Podmetrics withdrew its declare.
In 2022, Podimetrics scored $45 million in a Sequence C financing spherical. The capital was used to increase Podimetrics’ product improvement and analysis groups in addition to improve the variety of companies offered by its nurse help groups.
In 2019, Podimetrics raised $13.4 million in Sequence B funding. Rock Well being, Norwich Ventures and Scientific Well being Improvement participated within the spherical.
Different firms within the diabetes area embody Dexcom, which in 2024 made a $75 million strategic funding in health-tracking ring maker Oura and established a strategic partnership to allow two-way knowledge movement between Dexcom’s steady glucose monitor (CGM) and the Oura Ring. Dexcom’s $75 million funding introduced Oura’s valuation to greater than $5 billion.
Diabetes and insulin administration software program firm Glytec and pharmaceutical agency Roche joined forces final 12 months to permit using Glytec’s software program in reference to Roche’s point-of-care smart-device hospital blood glucose system cobas pulse within the U.S. and international markets.
In response to Roche, cobas pulse’s strip structure supplies lab-like outcomes and lowers the necessity to repeat assessments. The system can be utilized on all affected person populations, together with neonates and intensive care sufferers.
